Ligong Lu
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 2%
Papers in
-
- RNA modifications and cancer 13
- Hepatology 54
- Hepatocellular Carcinoma Treatment and Prognosis 44
- Co-authors
- Meixiao Zhan (84 shared papers)Xu He (30 shared papers)Wei Zhao (19 shared papers)You‐Wen He (5 shared papers)Danielle J. Dauphars (4 shared papers)Shaojun Peng (10 shared papers)Hui Zhang (2 shared papers)Yongjie Xin (16 shared papers)
- Journals
- Journal of Nanobiotechnology (5 papers)Cell Death and Disease (5 papers)Journal of Clinical Oncology (5 papers)Frontiers in Immunology (5 papers)Frontiers in Oncology (4 papers)
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Ligong Lu
210 papers receiving 6.4k citations
Ligong Lu's Hit Papers
Peers
Comparison fields: 5 of 150
- Hepatology 853
- Cancer Research 802
- Biomaterials 595
- Immunology 762
- Oncology 864
Countries citing papers authored by Ligong Lu
This map shows the geographic impact of Ligong Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ligong Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ligong Lu more than expected).
Fields of papers citing papers by Ligong Lu
This network shows the impact of papers produced by Ligong Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ligong Lu. The network helps show where Ligong Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Ligong Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 217 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Exosomes from adipose-derived stem cells overexpressing Nrf2 accelerate cutaneous wound healing by promoting vascularization in a diabetic foot ulcer rat model Hit paper breakdown → | 2018 | 417 |
| 2 | 2019 | 320 | |
| 3 | 2014 | 266 | |
| 4 | 2020 | 224 | |
| 5 | γδ T cells: origin and fate, subsets, diseases and immunotherapy Hit paper breakdown → | 2023 | 188 |
| 6 | 2020 | 138 | |
| 7 | Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell Hit paper breakdown → | 2023 | 129 |
| 8 | 2020 | 114 | |
| 9 | 2015 | 106 | |
| 10 | 2018 | 102 | |
| 11 | 2023 | 92 | |
| 12 | 2021 | 91 | |
| 13 | 2020 | 90 | |
| 14 | 2022 | 75 | |
| 15 | 2021 | 75 | |
| 16 | 2017 | 74 | |
| 17 | 2019 | 74 | |
| 18 | 2016 | 71 | |
| 19 | 2018 | 70 | |
| 20 | 2019 | 67 |
About Ligong Lu
Ligong Lu is a scholar working on Molecular Biology, Hepatology, Oncology, Biomedical Engineering and Pulmonary and Respiratory Medicine, having authored 217 papers that have together received 6.5k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (44 papers), Nanoplatforms for cancer theranostics (29 papers), Cancer Immunotherapy and Biomarkers (16 papers), RNA modifications and cancer (13 papers), Cancer Mechanisms and Therapy (12 papers), Nanoparticle-Based Drug Delivery (12 papers), Ferroptosis and cancer prognosis (10 papers) and Immune Cell Function and Interaction (10 papers). The work is most often cited by research in Hepatology (853 citations), Cancer Research (802 citations), Biomaterials (595 citations), Immunology (762 citations) and Oncology (864 citations). Ligong Lu has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Meixiao Zhan, Xu He, Wei Zhao, You‐Wen He, Danielle J. Dauphars, Shaojun Peng, Hui Zhang, Yongjie Xin, Xiaoyun Xie and Maoquan Li. Their work appears in journals such as Journal of Nanobiotechnology, Cell Death and Disease, Journal of Clinical Oncology, Frontiers in Immunology and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.